spur News
Most Popular spur Story
Insulin debate spurs push for generic biologics
The heat is on the FDA to find a way to approve a generic insulin, the oldest existing biologic on the market. And some observers say that the push is likely to spur a broader effort for a generic regulatory pathway for all biologics. Insulin has been used in form or another since the 1920s, but there has never been a generic form approved. Some $3.3 billion dollars a year is spent on insulin.
- read the …
Read more...Latest Headlines
- November 27, 2007
- September 26, 2007
- July 23, 2007
- January 10, 2007
- September 10, 2006
- August 27, 2006
- August 8, 2006
- July 19, 2006
- May 17, 2006
- March 29, 2006
- February 13, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
